| 生物制剂治疗系统性硬化病的研究进展 |
| |
| 引用本文： | 樊雪,朱晨雨,孙秋宁. 生物制剂治疗系统性硬化病的研究进展[J]. 国际皮肤性病学杂志, 2016, 0(2): 68-71. DOI: 10.3760/cma.j.issn.1673-4173.2016.02.003 |
| |
| 作者姓名： | 樊雪 朱晨雨 孙秋宁 |
| |
| 作者单位： | 中国医学科学院北京协和医学院北京协和医院皮肤科,北京,100730 |
| |
| 摘 要： | 系统性硬化病是一种以皮肤及各系统胶原纤维硬化为主要特征的慢性自身免疫性疾病,以免疫调节、减少纤维化和改善血液循环为基础的传统疗法,但疗效欠佳.近年来愈来愈多的证据显示,T淋巴细胞、B淋巴细胞及多种细胞因子在系统性硬化病的发病中起重要作用.研究显示,依那西普、英夫利西单抗、利妥昔单抗等生物制剂治疗难治性系统性硬化病疗效显著.
|
| 关 键 词： | 硬皮病,系统性 关节炎 生物制剂 治疗应用 药物毒性 |
Biological agents in the treatment of systemic sclerosis |
| |
| Abstract: | Systemic sclerosis is a chronic autoimmune disease characterized by fibrosclerosis of the skin and various internal organs.Efficacy of traditional therapies based on immune regulation,reduction of fibrosis and improvement of blood circulation is usually poor.In recent years,more and more evidences have demonstrated that T lymphocytes,B lymphocytes and various cytokines play important roles in the pathogenesis of systemic sclerosis.Studies also have shown that biological agents such as etanercept,infliximab and rituximab have remarkable therapeutic effects on refractory systemic sclerosis. |
| |
| Keywords: | Scleroderma,systemic Arthritis Biological agents Therapeutic uses Drug toxicity |
| 本文献已被 万方数据 等数据库收录！ |
|
